Novo Nordisk Places R&D Under the Microscope
A new medicine can take a 10 to 13 year journey from idea to patient, where scientists must navigate uncertainty, ethical dilemmas and unmet patient needs. The latest issue of TBL Quarterly explains the power and responsibility of science.
December 11, 2014 /3BL Media/ – Today, Novo Nordisk published a new issue of its quarterly sustainability magazine, TBL Quarterly. Last year, Novo Nordisk invested DKK 10.9 billion (approx. EUR 1.46 billion) in research and development (R&D) thereby supporting new drug development, global research collaboration and job creation.
In the new TBL Quarterly, Under the microscope: There’s more to R&D than meets the eye , Novo Nordisk employees discuss how science is making a positive contribution to health, society and the environment.
Novo Nordisk’s Chief Science Officer, Mads Krogsgaard Thomsen, sets the scene in the new issue which features articles, interviews, videos and infographics that provide an inside view of how R&D is conducted responsibly at Novo Nordisk.
Feature articles include how global research collaborations are advancing scientific progress, a new innovation in reducing and refining the number of animals used in research and testing, how social scientists are helping to uncover unmet patient needs and the positive role R&D plays in decreasing the environmental impact from production.
Download the new issue – ‘Under the microscope: There’s more to R&D than meets the eye’
The TBL Quarterly is published four times a year. If you want to receive notification when new issues are available, send a mail to sustainability@novonordisk.com.
About TBL Quarterly
Novo Nordisk manages its business in accordance with the Triple Bottom Line (TBL) business principle and pursues business solutions that maximise value to both the company and its stakeholders. Through selected themes, new perspectives and personal stories, the TBL Quarterly demonstrates how our TBL business principle supports long-term value creation. The TBL Quarterly is available as a reader-friendly PDF.
Explore previous issues of the TBL Quarterly
About Novo Nordisk
Headquartered in Denmark, Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy.
Novo Nordisk strives to conduct its activities in a financially, environmentally and socially responsible way. The strategic commitment to corporate sustainability has brought the company onto centre stage as a leading player in today’s business environment, recognised for its integrated reporting, stakeholder engagement and consistently high sustainability performance.
Read more about Novo Nordisk’s Triple Bottom Line approach to business
